Temperature dysregulation during therapeutic hypothermia predicts long-term outcome in neonates with HIE

J Cereb Blood Flow Metab. 2023 Jul;43(7):1180-1193. doi: 10.1177/0271678X231162174. Epub 2023 Mar 8.

Abstract

Few reliable or easily obtainable biomarkers to predict long-term outcome in infants with hypoxic-ischemic encephalopathy (HIE) have been identified. We previously showed that mattress temperature (MT), as proxy for disturbed temperature regulation during therapeutic hypothermia (TH), predicts injury on early MRI and holds promise as physiologic biomarker. To determine whether MT in neonates treated with TH for moderate-severe HIE is associated with long-term outcome at 18-22 months, we performed a secondary analysis of the Optimizing Cooling trial using MT data from 167 infants treated at a core temperature of 33.5°C. Median MTs from four time-epochs (0-6 h, 6-24 h, 24-48 h, and 48-72 h of TH) were used to predict death or moderate-severe neurodevelopmental impairment (NDI), using epoch-specific derived and validated MT cutoffs. Median MT of infants who died or survived with NDI was consistently 1.5-3.0°C higher throughout TH. Infants requiring a median MT above the derived cut-offs had a significantly increased odds of death or NDI, most notably at 0-6 h (aOR 17.0, 95%CI 4.3-67.4). By contrast, infants who remained below cut-offs across all epochs had 100% NDI-free survival. MTs in neonates with moderate-severe HIE during TH are highly predictive of long-term outcome and can be used as physiologic biomarker.

Keywords: Hypoxic-ischemic encephalopathy; biomarker; neurodevelopmental outcome; therapeutic hypothermia; thermoregulation.

MeSH terms

  • Biomarkers
  • Humans
  • Hypothermia, Induced*
  • Hypoxia-Ischemia, Brain* / complications
  • Hypoxia-Ischemia, Brain* / diagnostic imaging
  • Hypoxia-Ischemia, Brain* / therapy
  • Infant
  • Infant, Newborn
  • Magnetic Resonance Imaging
  • Temperature

Substances

  • Biomarkers